[1] S. Bensen, L. A. Mott, B. Dain, R. Rothstein, J. Baron, “The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group,” Am. J. Gastroenterol. 94(1), 194–199 (1999).

[2] J. C. van Rijn, J. B. Reitsma, J. Stoker, P. M. Bossuyt, S. J. van Deventer, E. Dekker, “Polypmiss rate determined by tandem colonoscopy: A systematic review,” Am. J. Gastroenterol. 101(2), 343–350 (2006).

[3] R. S. DaCosta, B. C.Wilson, N. E.Marcon, “Optical techniques for the endoscopic detection of dysplastic colonic lesions,” Curr. Opin. Gastroenterol. 21(1), 70–79 (2005).

[4] R. S. DaCosta, B. C. Wilson, N. E. Marcon, “New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions,” J. Gastroenterol. Hepatol. 17, S85–104 (2002).

[5] J. Haringsma, G. N. Tytgat, H. Yano, H. Iishi, M. Tatsuta, T. Ogihara, H.Watanabe, N. Sato, N. Marcon, B. C. Wilson, R. W. Cline, “Autofluorescence endoscopy: Feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology,” Gastrointest. Endosc. 53(6), 642– 650 (2001).

[6] M. Kara, R. S. DaCosta, B. C. Wilson, N. E. Marcon, J. Bergman, “Autofluorescence-based detection of early neoplasia in patients with Barrett’s esophagus,” Dig. Dis. 22(2), 134–141 (2004).

[7] S. Brand, T. D. Wang, K. T. Schomacker, J. M. Poneros, G. Y. Lauwers, C. C. Compton, M. C. Pedrosa, N. S. Nishioka, “Detection of high-grade dysplasia in Barrett’s esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence,” Gastrointest. Endosc. 56(4), 479–487 (2002).

[8] B. Mayinger, S. Neidhardt, H. Reh, P. Martus, E. G. Hahn, “Fluorescence induced with 5-aminolevulinic acid for the endoscopic detection and follow-up of esophageal lesions,” Gastrointest. Endosc. 54(5), 572–578 (2001).

[9] H. Messmann, “5-aminolevulinic acid-induced protoporphyrin IX for the detection of gastrointestinal dysplasia,” Gastrointest. Endosc. Clin. N. Am. 10(3), 497–512 (2000).

[10] L. Gossner, M. Stolte, R. Sroka, K. Rick, A. May, E. G. Hahn, C. Ell, “Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid,” Gastroenterology 114(3), 448–455 (1998).

[11] W. C. Tan, C. Fulljames, N. Stone, A. J. Dix, N. Shepherd, D. J. Roberts, S. B. Brown, N. Krasner, H. Barr, “Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett’s metaplasia,” J. Photochem. Photobiol. B. 53(1–3), 75–80 (1999).

[12] R. Ackroyd, N. J. Brown, M. F. Davis, T. J. Stephenson, C. J. Stoddard, M. W. Reed, “Aminolevulinic acid-induced photodynamic therapy: Safe and effective ablation of dysplasia in Barrett’s esophagus,” Dis. Esophagus. 13(1), 18–22 (2000).

[13] H. Messmann, R. Knuchel, W. Baumler, A. Holstege, J. Scholmerich, “Endoscopic fluorescence detection of dysplasia in patients with Barrett’s esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization,” Gastrointest. Endosc. 49(1), 97– 101 (1999).

[14] S. B. Ho, Y. S. Kim, “Carbohydrate antigens on cancer-associated mucin-like molecules,” Semin. Cancer Biol. 2(6), 389–400 (1991).

[15] Y. S. Kim, “Altered glycosylation of mucin glycoproteins in colonic neoplasia,” J. Cell. Biochem. 16, 91–96 (1992).

[16] N. Aksoy, O. F. Akinci, “Mucin macromolecules in normal, adenomatous, and carcinomatous colon: Evidence for the neotransformation,” Macromol. Biosci. 4(5), 483–496 (2004).

[17] S. E. Baldus, F. G. Hanisch, “Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia,” Adv. Cancer Res. 79, 201–248 (2000).

[18] C. R. Boland, C. K. Montgomery, Y. S. Kim, “Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation,” Proc. Natl. Acad. Sci. U.S.A. 79(6), 2051–2055 (1982).

[19] J. C. Byrd, R. S. Bresalier, “Mucins and mucin binding proteins in colorectal cancer,” Cancer Metastasis Rev. 23(1–2), 77–99 (2004).

[20] S. B. Ho, S. L. Ewing, C. K. Montgomery, Y. S. Kim, “Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence,” Oncol. Res. 8(2), 53–61 (1996).

[21] D. J. Buchsbaum, M. B. Khazaeli, M. S. Mayo, P. L. Roberson, “Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model,” Clin. Cancer Res. 5(10 Suppl), 3153s–3159s (1999).

[22] F. Guadagni, M. Roselli, M. Cosimelli, P. Ferroni, A. Spila, F. Cavaliere, R. Arcuri, S. Carlini, S. Mariotti, G.M. Gandolfo, C. U. Casciani, J. W. Greiner, J. Schlom, “TAG72 expression and its role in the biological evaluation of human colorectal cancer,” Anticancer Res. 16(4B), 2141–2148 (1996).

[23] M. Roselli, F. Guadagni, O. Buonomo, A. Belardi, P. Ferroni, A. Diodati, D. Anselmi, C. Cipriani, C. U. Casciani, J. Greiner, J. Schlom, “Tumor markers as targets for selective diagnostic and therapeutic procedures,” Anticancer Res. 16(4B), 2187–2192 (1996).

[24] D. J. Yang, E. E. Kim, T. Inoue, “Targeted molecular imaging in oncology,” Ann. Nucl. Med. 20(1), 1–11 (2006).

[25] S. H. Britz-Cunningham, S. J. Adelstein, “Molecular targeting with radionuclides: State of the science,” J. Nucl. Med. 44(12), 1945–1961 (2003).

[26] R. F. Meredith, A. J. Bueschen, M. B. Khazaeli, W. E. Plott, W. E. Grizzle, R. H. Wheeler, J. Schlom, C. D. Russell, T. Liu, A. F. LoBuglio, “Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49,” J. Nucl. Med. 35(6), 1017–1022 (1994).

[27] C. R. Divgi, A. M. Scott, L. Dantis, P. Capitelli, K. Siler, S. Hilton, R. D. Finn, N. Kemeny, D. Kelsen, L. Kostakoglu et al., “Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma,” J. Nucl. Med. 36(4), 586–592 (1995).

[28] R. J. Domingo, R. M. Reilly, “Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin,” Nucl. Med. Commun. 21(1), 89–96 (2000).

[29] D. J. Buchsbaum, B. E. Rogers, M. B. Khazaeli, M. S. Mayo, D. E. Milenic, S. V. Kashmiri, C. J. Anderson, L. L. Chappell, M. W. Brechbiel, D. T. Curiel, “Targeting strategies for cancer radiotherapy,” Clin. Cancer Res. 5(10 Suppl), 3048s–3055s (1999).

[30] D. Buchsbaum, M. B. Khazaeli, T. Liu, S. Bright, K. Richardson, M. Jones, R. Meredith, “Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49,” Cancer Res. 55(23 Suppl), 5881s–5887s (1995).

[31] B. Ballou, G. W. Fisher, T. R. Hakala, D. L. Farkas, “Tumor detection and visualization using cyanine fluorochrome-labeled antibodies,” Biotechnol. Prog. 13(5), 649–658 (1997).

[32] V. Ntziachristos, “Fluorescence molecular imaging,” Annu. Rev. Biomed. Eng. 8, 1–33 (2006).

[33] D. C. Andersen, D. E. Reilly, “Production technologies for monoclonal antibodies and their fragments,” Curr. Opin. Biotechnol. 15(5), 456–462 (2004).

[34] A. Thor, N. Ohuchi, C. A. Szpak, W. W. Johnston, J. Schlom, “Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3,” Cancer Res. 46(6), 3118– 3124 (1986).

[35] H. Andersson, T. Baechi, M. Hoechl, C. Richter, “Autofluorescence of living cells,” J. Microsc. 191(Pt 1), 1–7 (1998).

[36] R. DaCosta, “Mechanisms of fluorescence endoscopy of the human colon,” in Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada (1999).

[37] B. Ballou, G. W. Fisher, A. S. Waggoner, D. L. Farkas, J. M. Reiland, R. Jaffe, R. B. Mujumdar, S. R. Mujumdar, T. R. Hakala, “Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies,” Cancer Immunol. Immunother. 41(4), 257– 263 (1995).

[38] S. Folli, P. Westermann, D. Braichotte, A. Pelegrin, G. Wagnieres, H. van den Bergh, J. P. Mach, “Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice,” Cancer Res. 54(10), 2643–2649 (1994).

[39] S. Ito, N. Muguruma, Y. Kusaka, M. Tadatsu, K. Inayama, Y. Musashi, M. Yano, T. Bando, H. Honda, I. Shimizu, K. Ii, K. Takesako, H. Takeuchi, S. Shibamura, “Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro,” Endoscopy 33(10), 849–853 (2001).

[40] N. Muguruma, S. Ito, T. Bando, S. Taoka, Y. Kusaka, S. Hayashi, S. Ichikawa, Y. Matsunaga, Y. Tada, S. Okamura, K. Ii, K. Imaizumi, K. Nakamura, K. Takesako, S. Shibamura, “Labeled carcinoembryonic antigen antibodies excitable by infrared rays: A novel diagnostic method for microcancers in the digestive tract,” Intern. Med. 38(7), 537–542 (1999).

[41] T. Bando, N. Muguruma, S. Ito, Y. Musashi, K. Inayama, Y. Kusaka, M. Tadatsu, I. Kunio, T. Irimura, S. Shibamura, K. Takesako, “Basic studies on a labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy,” J. Gastroenterol. 37(4), 260–269 (2002).

[42] P. Carter, L. Smith, M. Ryan, “Identification and validation of cell surface antigens for antibody targeting in oncology,” Endocr. Relat. Cancer 11(4), 659–687 (2004).

[43] P. A. Edwards, “Heterogeneous expression of cellsurface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies,” Br. J. Cancer 51(2), 149–160 (1985).

[44] X. Montet, V. Ntziachristos, J. Grimm, R. Weissleder, “Tomographic fluorescence mapping of tumor targets,” Cancer Res. 65(14), 6330–6336 (2005).

[45] A. Bogaards, “In vivo fluorescence imaging of markers for detection and guided resection of cancer,” Erasmus University, Rotterdam, The Netherlands (2006).

[46] J. H. Lee, J. W. Kim, Y. K. Cho, C. I. Sohn, W. K. Jeon, B. I. Kim, E. Y. Cho, “Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine,” Am. J. Gastroenterol. 98(6), 1284–1288 (2003).

[47] H. Sezaki, “Mucosal penetration enhancement,” J. Drug. Target. 3(3), 175–177 (1995).

[48] S. Takatsuka, T. Kitazawa, T. Morita, Y. Horikiri, H. Yoshino, “Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant,” Eur. J. Pharm. Biopharm. 62(1), 52–58 (2006).

[49] K. P. Janssen, D. Vignjevic, R. Boisgard, T. Falguieres, G. Bousquet, D. Decaudin, F. Dolle, D. Louvard, B. Tavitian, S. Robine, L. Johannes, “In vivo tumor targeting using a novel intestinal pathogen-based delivery approach,” Cancer Res. 66(14), 7230–7236 (2006).

[50] R. Kiesslich, M. Goetz, M. Vieth, P. R. Galle, M. F. Neurath, “Confocal laser endomicroscopy,” Gastrointest. Endosc. Clin. N. Am. 15(4), 715–731 (2005).

[51] B. C.Wolf, J. C. D’Emilia, R. R. Salem, D. DeCoste, H. F. Sears, L. S. Gottlieb, G. D. Steele, Jr., “Detection of the tumor-associated glycoprotein antigen (TAG72) in premalignant lesions of the colon,” J. Natl. Cancer Inst. 81(24), 1913–1917 (1989).

[52] A. Thor, S. H. Itzkowitz, J. Schlom, Y. S. Kim, S. Hanauer, “Tumor-associated glycoprotein (TAG72) expression in ulcerative colitis,” Int. J. Cancer 43(5), 810–815 (1989).

[53] B. E. Rogers, P. L. Roberson, S. Shen, M. B. Khazaeli, M. Carpenter, S. Yokoyama, M. W. Brechbiel, A. F. LoBuglio, D. J. Buchsbaum, “Intraperitoneal radioimmunotherapy with a humanized anti-TAG72 (CC49) antibody with a deleted CH2 region,” Cancer Biother. Radiopharm. 20(5), 502–513 (2005).

[54] J. Xiao, S. Horst, G. Hinkle, X. Cao, E. Kocak, J. Fang, D. Young, M. Khazaeli, D. Agnese, D. Sun, E. Martin, Jr., “Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients,” Cancer Biother. Radiopharm. 20(1), 16–26 (2005).

[55] D. M. Agnese, S. F. Abdessalam, W. E. Burak, Jr., M. W. Arnold, D. Soble, G. H. Hinkle, D. Young, M. B. Khazaeli, E. W. Martin, Jr., “Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma,”Ann. Surg.Oncol.11(2), 197–202 (2004).

[56] M. A. Ortner, G. Dorta, A. L. Blum, P. Michetti, “Endoscopic interventions for preneoplastic and neoplastic lesions: Mucosectomy, argon plasma coagulation, and photodynamic therapy,” Dig. Dis. 20(2), 167–172 (2002).

[57] R. H. Hawes, “Perspectives in endoscopic mucosal resection,” Gastrointest. Endosc. Clin. N. Am. 11(3), 549–552 (2001).

[58] R. J. Cote, D. P. Houchens, C. L. Hitchcock, A. D. Saad, R. G. Nines, J. K. Greenson, S. Schneebaum, M. W. Arnold, E. W. Martin, Jr., “Intraoperative detection of occult colon cancer micrometastases using 125I-radiolabeled monoclonal antibody CC49,” Cancer 77(4), 613–620 (1996).

[59] K. Ikawa, Y. Terashima, K. Sasaki, S. Tashiro, “Genetic detection of liver micrometastases that are undetectable histologically,” J. Surg. Res. 106(1), 124–130 (2002).

[60] M. J. Koppe, A. C. Soede, W. Pels, W. J. Oyen, D. M. Goldenberg, R. P. Bleichrodt, O. C. Boerman, “Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin,” Int. J. Cancer 106(6), 965–972 (2003).

[61] J. K. Greenson, C. E. Isenhart, R. Rice, C. Mojzisik, D. Houchens, E. W. Martin, Jr., “Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival,” Cancer 73(3), 563–569 (1994).

[62] R. Muraro, M. Kuroki, D. Wunderlich, D. J. Poole, D. Colcher, A. Thor, J. W. Greiner, J. F. Simpson, A. Molinolo, P. Noguchi et al., “Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen,” Cancer Res. 48(16), 4588– 4596 (1988).

[63] M. Guindi, R. H. Riddell, “The pathology of epithelial pre-malignancy of the gastrointestinal tract,” Best Pract. Res. Clin. Gastroenterol. 15(2), 191–210 (2001).

[64] F. Yuan, M. Leunig, D. A. Berk, R. K. Jain, “Microvascular permeability of albumin, vascular surface area, and vascular volumemeasured in human adenocarcinoma LS174T using dorsal chamber in SCID mice,” Microvasc. Res. 45(3), 269–289 (1993).

[65] F. Yuan, M. Dellian, D. Fukumura,M. Leunig, D. A. Berk, V. P. Torchilin, R. K. Jain, “Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size,” Cancer Res. 55(17), 3752–3756 (1995).

[66] S. M. Larson, A. M. El-Shirbiny, C. R. Divgi, G. Sgouros, R. D. Finn, J. Tschmelitsch, A. Picon, M. Whitlow, J. Schlom, J. Zhang, A. M. Cohen, “Single chain antigen binding protein (sFv CC49): First human studies in colorectal carcinoma metastatic to liver,” Cancer 80(12 Suppl), 2458–2468 (1997).

[67] Y. Tang, S. Yang, J. Gari′epy, D. Scollard, R. Reilly, “Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically-generated Fab fragments of the TAG72 monoclonal antibody CC49,” Bioconjug. Chem. 18(3), 677–684 (2007).

[68] J. Gui, T. Moyana, B. Malcolm, J. Xiang, “Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library,” Proteins 24(3), 352–358 (1996).

[69] A. Becker, C. Hessenius, K. Licha, B. Ebert, U. Sukowski, W. Semmler, B. Wiedenmann, C. Grotzinger, “Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands,” Nat. Biotechnol. 19(4), 327–331 (2001).

[70] K. Kelly, H. Alencar, M. Funovics, U. Mahmood, R. Weissleder, “Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide,” Cancer Res. 64(17), 6247–6251 (2004).

[71] R. K. Jain, “Transport of molecules, particles, and cells in solid tumors,” Annu. Rev. Biomed. Eng. 1, 241–263 (1999).

[72] J. W. Greiner, F. Guadagni, M. Roselli, C. A. Nieroda, “Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine,” Anticancer Res. 16(4B), 2129–2133 (1996).

[73] M. Roselli, F. Guadagni, O. Buonomo, A. Belardi, V. Vittorini, R. Mariani-Costantini, J. W. Greiner, C. U. Casciani, J. Schlom, “Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen,” J. Clin. Oncol. 14(7), 2031–2042 (1996).

[74] O. Veiseh, C. Sun, J. Gunn, N. Kohler, P. Gabikian, D. Lee, N. Bhattarai, R. Ellenbogen, R. Sze, A. Hallahan, J. Olson, M. Zhang, “Optical and MRI multifunctional nanoprobe for targeting gliomas,” Nano Lett. 5(6), 1003–1008 (2005).